<DOC>
	<DOCNO>NCT01890473</DOCNO>
	<brief_summary>The primary purpose protocol describe pharmacokinetics single dose Abatacept 125 mg Rheumatoid Arthritis patient deliver via autoinjector device approve prefilled syringe .</brief_summary>
	<brief_title>Study Characterize Pharmacokinetics Single Dose SC Abatacept 125 mg Using BD Autoinjector Prefilled Syringe</brief_title>
	<detailed_description>SC=Subcutaneous</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Key Subjects ≥18 year age Diagnosis Rheumatoid Arthritis confirm participant 's physician Disease activity control Key Change diseasemodifying antirheumatic drug ( DMARD ) therapy within 3 month enrollment Exposure investigational drug within 4 week 5 half life whichever longer Current prior use Rituximab ≤6 month Current prior use follow within 4 week 5 half life whichever longer : biologic DMARDS , Tofacitinib , Cyclophosphamide , Mycophenolate Mofetil &amp; dPenicillamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>